Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances
Cureus · 29.08.2023
DOI: 10.7759/cureus.44302 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cureus, erschienen am 29.08.2023. Verfasst von Chukwuyem Ekhator und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This narrative review provides an overview of the current advances, challenges, and opportunities in nanoparticle drug delivery for central nervous system (CNS) disorders. The treatment of central nervous system disorders is challenging due to the blood-brain barrier (BBB), which limits the delivery of therapeutic agents to the brain. Promising approaches to address these issues and improve the efficacy of CNS disease therapies are provided by nanoparticle-based drug delivery systems. Nanoparticles, such as liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles, can be modified to enhance targeting, stability, and drug-release patterns. They allow for the encapsulation of a variety of therapeutic compounds and can be functionalized with ligands or antibodies for active targeting, minimizing off-target effects. Additionally, nanoparticles can circumvent drug resistance processes and provide versatile platforms for applications that combine therapeutic and diagnostic functions. Although the delivery of CNS medications using nanoparticles has advanced significantly, there are still challenges to be resolved. These include understanding the BBB interactions, doing long-term safety studies, and scaling up the production. However, improvements in nanotechnology and a deeper comprehension of CNS disorders provide opportunities to enhance treatment results and address unmet medical requirements. Future research and ongoing clinical trials are required to further explore the potential of nanoparticle drug delivery for CNS disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuro-Oncology, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, USA.
- Medicine and Surgery, Mayo Hospital, Lahore, PAK.
- Medicine and Surgery, Dow University of Health Sciences, Karachi, PAK.
- Internal Medicine, Mayo Hospital, Lahore, PAK.
- Psychiatry, College of Medical Scieces, Bharatpur, NPL.
- Internal Medicine, University of Medicine and Health Sciences, Basseterre, KNA.
Zitieren
APA
Ekhator, C., Qureshi, M. Q., Zuberi, A. W., Hussain, M., Sangroula, N., Yerra, S., Devi, M., Naseem, M. A., Bellegarde, S. B., & Pendyala, P. R. (2023). Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances. Cureus. https://doi.org/10.7759/cureus.44302
Vancouver
Ekhator C, Qureshi MQ, Zuberi AW, Hussain M, Sangroula N, Yerra S, et al. Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances. Cureus. 2023. doi:10.7759/cureus.44302
BibTeX
@article{Ekhator2023,
author = {Ekhator, Chukwuyem and Qureshi, Muhammad Qasim and Zuberi, Abdul Wasay and Hussain, Muqaddas and Sangroula, Niraj and Yerra, Sushanth and Devi, Monika and Naseem, Muhammad Arsal and Bellegarde, Sophia B and Pendyala, Praful R},
title = {Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances},
journal = {Cureus},
year = {2023},
doi = {10.7759/cureus.44302}
}
EUVIMED